原題
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Journal: Ann Oncol (CiteScore 2022: 63)
DOI: 10.1016/j.annonc.2026.05.694
PMID: 42162664